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1 Abbreviations 
 
3-NP 3-Nitropropionic Acid 
AD Alzheimer’s Disease 
AGD Argyrophilic Grain Disease 
ALS Amyotrophic Lateral Sclerosis 
AMPA α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid  
AP Atypical Parkinsonism 
ATP Adenosine Triphosphate 
BBB Blood Brain Barrier 
BMAA β-Methylamino-L-Alanine 
BSSG β-Sitosterol β-d-Glucoside 
C/EBP CCAAT-Enhancer-Binding Proteins  
CBD Corticobasilar Degeneration 
CCCP Carbonyl Cyanide m-Chlorophenylhydrazone  
CHIP Carboxyl Terminus HSP70/90 Interacting Protein 
CHOP C/EBP Homologous Protein 
CSF Cerebrospinal Fluid 
DAergic Dopaminergic 
DMA Dendrite-Morphogenesis-Abnormal 
EAAs Excitatory Amino Acids 
ER Endoplasmic Reticulum 
FTD Frontotemporal Dementia 
Gd-PDC/PSP Guadeloupean Parkinsonism Dementia 
Complex/Progressive Supranuclear Palsy 
GSK-3B Glycogen Synthase Kinase 3 Beta 
HDAC6 Histone Deacetylase 6 
 
IGF1 Insulin-like Growth Factor-1 
L-BOAA Beta-Oxalylamino-L-Alanine 
LAT1 L-type Amino Acid Transporter 1 
Lrrk2 Leucine-rich repeat kinase 2  
LSP Lipoprotein Signal Peptide 
MAM Methylazoxymethanol 
MAP Microtubule Associated Protein 
MAPT Microtubule-Associated Protein Tau (Gene) 
MD Mariana’s Dementia 
mGluR5 Metabotropic Glutamate Receptor 5 
MPP+ 1-Methyl-4-Phenylpyridinium 
MRI Magnetic Resonance Imaging 
 ii 
NDDs Neurodegenerative Diseases 
NFTs Neurofibrillary Tangles 
NMDA N-Methyl-D-Aspartate Receptor  
PD Parkinson’s Disease 
PDC Parkinsonism Dementia Complex 
PHF Paired Helical Fragments 
PiD Pick’s Disease 
PP1, PP2A and 
PP2B 
Tau Phosphatases  
PP2AC Catalytic Subunit of Protein Phosphatase 2A  
PSP Progressive Supranuclear Palsy 
RBD REM-sleep Behavior Disorder  
REM Rapid Eye Movement 
ROS Reactive Oxygen Species 
Ser262 Serine Residue Number 262 
SG Sterol Glucosides 
SNO Supranuclear Ophthalmoplegia 
SPECT Single-photon Emission Computed Tomography  
Src Steroid Receptor Coactivator 
SRSF2 Serine/Arginine-Rich Splicing Factor 2 
TDP-43 Transactive Response DNA Binding Protein 43 kDa 
Thr 231 Threonine Residue Number 231 
TRPM Transient Receptor Potential Cation Channel,  
Subfamily M 
TRPM2 Transient Receptor Potential Cation Channel, Subfamily 
M, Member 2 
TRPM7 Transient Receptor Potential Cation Channel, Subfamily 
M, Member 7 
Tyr307 Tyrosine Residue 307 
UMN Upper Motor Neuron 
UPR Unfolded Protein Response 
WWII World War Two 
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3 Summary 
 
Title:   Environmental Tauopathies 
Author:  Cari Green 
 
Neurodegenerative diseases, of which tauopathies form a major class, are increasing 
in prevalence worldwide. Tauopathies are characterized by the presence of abnormal 
neuronal and glial inclusions that are composed predominantly of the microtubule 
associated protein, tau. Several foci of increased incidence of tauopathies have been 
identified that have been attributed to environmental neurotoxins. Exposure to 
inorganic or organic toxins (such as β-Methylamino-L-Alanine  and annonacin) 
through water, food and traditional medical practices is the suspected etiology but it 
remains to be proven whether these are sole sufficient factors. These progressive 
and uniformly fatal diseases are characterized clinically by various combinations of 
dementia, parkinsonism and motor neuron disease. This review attempts to 
summarize the currently available information on small geographic clusters of 
endemic environmental tauopathies that have been identified in the Chamarros of 
Guam, inhabitants of the Kii Peninsula in Japan, members of the Auyu and Jaqai 
groups in Papa New Guinea, and residents of Guadeloupe. Possible unifying 
neurodegenerative mechanisms are explored in relation to sporadic tauopathies 
worldwide.  
 
Keywords: ALS/PDC; annonacin; atypical parkinsonism; cycads; L-BMAA; lytico-
bodig; tauopathy                 
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4 Introduction 
The search for the primary etiology of neurodegenerative diseases has largely 
revolved around genetic studies, a perspective that has been strengthened by the 
identification of mutations associated with Huntington’s disease, familial Alzheimer’s 
disease (AD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS). 
Despite years of extensive investigation into the role of genetic causation, the 
discovered mutations have thus far managed to account for no more than 10% of the 
ever-increasing neurodegenerative disease burden. While it is likely that future 
genetic discoveries will account for some of the remaining 90% of cases, it is at least 
equally likely that environmental factors such as neurotoxins play an important role in 
the development and increased incidence of neurodegenerative disease. Perhaps 
most likely of all is a scenario in which these diseases are due to multiple gene-
environment interactions mediated by epigenetic mechanisms. In the quest for a 
greater understanding of neurodegenerative disease, several foci of increased 
incidence of tauopathies, a subset of neurodegenerative diseases, have been 
identified that are attributed to environmental neurotoxicant exposures. This review 
attempts to summarize the information that is currently available on small geographic 
clusters of these environmentally caused tauopathies.  
 
Tauopathies are a heterogenous class of neurodegenerative diseases (NDDs) 
characterized by the presence of abnormal neuronal and/or glial inclusions that are 
composed predominantly of the microtubule associated protein, tau. Defined 
clinicopathologically, this group encompasses more than 25 recognized entities 
(Murray et al., 2014) that have historically been subdivided into primary (those 
diseases in which tau inclusions are believed to be the main cause of the disease) 
and secondary (tau inclusions occur but are not believed to be part of the primary 
process) tauopathies. A newer subclassification, based on biochemical structure, 
divides tauopathies into three groups according to the predominant tau isoform found 
in the inclusions, that is: 4R tauopathies (including progressive supranuclear palsy 
(PSP), corticobasilar degeneration (CBD), Huntington’s and argyrophilic grain 
disease (AGD)), 3R tauopathies (Pick’s disease) and 3R+4R tauopathies (for 
example, Alzheimer’s disease (AD)) (Dickson et al., 2011). Clinically, tauopathies are 
characterized by various combinations of parkinsonism, dementia, and motor neuron 
disorders. While some tauopathies have clearly been shown to be of genetic origin, 
the majority appear to occur sporadically, either as a result of environmental factors 
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alone or in combination with genetic susceptibility. Elucidating the cause of these 
clusters of “environmental” diseases would provide models for sporadic tauopathies 
and potentially lead to the discovery of new therapeutic interventions.   
 
5 Tau Protein 
5.1 Physiological Tau  
Tau protein was first purified from porcine brain and characterized as a member 
of the Microtubule-associated protein (MAP) family. It is distributed extensively 
throughout neurons and found at lower levels in astrocytes and oligodendrocytes. 
Under physiologic conditions it is relegated largely to the distal end of axons (Huang 
et al., 2015). In humans, tau has six isoforms (ranging from 352-441 amino acids in 
size) that are the products of alternative splicing from a single, 16 exon gene, 
Microtubule-Associated Protein Tau (MAPT), localized on chromosome 17q21. 
MAPT is over 50 kb in size with two haplotypes, H1 and H2, and multiple variants of 
each (Lee and Leugers, 2012). The differences among the isoforms are due to 
alternative splicing of exons 2, 3 and 10, which results in the presence or absence of 
29- or 58-amino acid long inserts (0N, 1N, or 2N) in the amino-terminal (N-terminal) 
region, as well as an additional 31-amino acid repeat (3R or 4R) in the carboxy-
terminal (C-terminal) region. Isoforms that include exon 10 are referred to as 4R 
while those that exclude exon 10 are referred to as 3R. 1N3R and 1N4R are the most 
abundant forms (Lee and Leugers, 2012). A relatively constant ratio of 3R/4R 
isoforms is maintained in the normal brain. The major known function of tau is to bind 
to microtubules and it has been shown that 4R isoforms exhibit a 40 times higher 
affinity for microtubule binding than 3R isoforms (Goode and Feinstein, 1994). The 
diversity of isoforms is increased by post-translational modifications, in particular, 
phosphorylation. Tau contains 85 serine (Ser), threonine (Thr), and tyrosine (Tyr) 
potential phosphorylation sites. Approximately 10 phosphorylation sites can be 
detected on soluble tau purified from a normal brain (Sun and Chen 2015). Tau is 
highly soluble in water and exhibits stability under acidic conditions and in high 
temperatures.  Overall, tau is a basic protein although the N-terminal is acidic and the 
C-terminal is neutral. The asymmetry of charge is likely important for microtubule 
interactions, folding, and aggregation (Wang and Mandelkow, 2015). Normal tau is 
natively unfolded and has little tendency for aggregation. The tau molecule tends to 
change its global conformation to form a shape similar to a paperclip, in which the N-
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terminal, C-terminal and the repeat domains all approach each other under 
physiological conditions.  Truncation of tau prevents this formation and may promote 
aggregation (Wang and Mandelkow, 2015).   
5.2 Pathological Tau 
To date, the pathological finding in every known tauopathy involves 
hyperphosphorylated tau protein. Tau normally contains 2-3 moles of phosphate per 
mole of the protein whereas pathological tau proteins in AD brains have been found 
to be 2-3 times more hyperphosphorylated (Iqbal et al., 2015).  Hyperphosphorylation 
(particularly at residues Ser262 and Thr231) significantly decreases the binding 
affinity of tau for microtubules. The resultant instability of the microtubules leads to 
their depolymerization, which directly affects axoplasmic transport, a function 
essential to neuron survival. The dissociated tau missorts to the cell body as well as 
becoming more diffusible (Huang et al., 2015). Small quantities of missorted tau 
appear to have the ability to influence normal tau protein to release microtubules and 
missort, eventually leading to pathological tau aggregation and ultimately, death of 
neurons (Huang et al. 2015). The protein subunit of neurofibrillary tangles (NFT) 
consists mostly of hyperphosphorylated tau which, is apparently inert and neither 
binds to tubulin nor promotes it assembly into microtubules (Iqbal et al., 2009).  It is 
the subject of an as yet unanswered debate which form of tau (aggregated 
misfolded/fibrillar, soluble hyperphosphorylated/mislocalized, or both) is in fact the 
most toxic (Šimić et al. 2016). Many studies have shown a direct correlation between 
the number and density of NFTs and the severity of symptoms in AD. On the other 
hand, recent findings have shown that NFT containing neurons can survive up to 20-
30 years (Huang et al., 2015), leading to the suspicion that they may not be the major 
toxic player. The most recent data suggests oligomerized forms of tau as the true 
source of toxicity (Huang et al., 2015) as they have been shown to appear early in 
the disease course and are highly toxic in in vitro and in vivo experiments. 
Complicating matters even further is the implication of several post-translational 
modifications leading to tau toxicity, which include: glycosylation, O-GlcNAcylation, 
acetylation and abnormal truncation.  Additionally, a common factor in several tau 
toxicity cascades involves the activity of the major tau phosphorylation regulation 
enzymes, the tau phosphatases (PP1, PP2A and PP2B). The activity of these 
phosphatases has been found altered in several tauopathies (Huang et al., 2015).   
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Figure 5-1: Normal and Pathological Tau Proteins. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Neuroscience (Wang Y, Mandelkow E. 
Tau in physiology and pathology. Nature Reviews 2015; doi:10.1038/nrn.2015.1.) 
 
 
6 ALS/PDC of the Western Pacific 
6.1 ALS/PDC/MD on Guam- “Lytico-bodig” disease 
6.1.1 Epidemiology 
Following the American recapture of Guam from the Japanese in 1944, army 
neurologist Zimmerman described a high incidence of amyotrophic lateral sclerosis 
(ALS) on the island. The first published reports came in 1952 and 1953 when army 
physicians Koerner and Arnold described a high incidence of ALS among the 
Chamarros on Guam, which was soon confirmed and expanded on in several studies 
by Kurland, Mulder and others (Koerner, 1952; Kurland and Mulder, 1954, 1955). 
The incidence of ALS on Guam peaked in the 1950s at 200/100,000 per year, 100 
times higher than elsewhere in the world (Bradley and Mash 2009). Soon after, a 
form of atypical parkinsonism often associated with dementia was also identified by 
Mulder, and later shown by Hirano to be a unique disease entity in high prevalence 
amongst the Chamarros on Guam (Plato et al., 2003). It was linked epidemiologically 
with ALS and shown to be a different phenotypic expression of the same disease, 
which became known as amyotrophic lateral sclerosis/parkinsonism- dementia 
complex (ALS/PDC). In some villages, one-third of adult deaths were due to 
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ALS/PDC (McConnell, 2004). It was known as lytico-bodig (idiotic and lazy in the 
Chamarro language) disease by the locals and references to it have been found in 
documents dating back to the late Spanish period (1700-1800) as well as in death 
certificates from the early 1900s (Bradley and Mash, 2009).  
 
Rather early, it was recognized that ALS/PDC occurred with a high prevalence 
in certain Chamarro families and with an uneven geographical distribution on the 
island. The highest incidence was found in the village of Umatac (10 times higher 
than elsewhere on Guam). Zhang and collaborators (1990) reported that the age-
adjusted incidence there was 273/100,000 in men and 222/100,000 in women while a 
mere 4 miles away it was 38/100,000. The identification of clustering within families 
initially prompted a search for a genetic cause. A house-to-house survey showed that 
more than 60% of cases were concentrated in a single pedigree. The disease was 
more prevalent in men, a fact that led researchers towards an explanation involving 
an autosomal dominant gene with 50% penetrance in women. Subsequent 
segregation analyses by Reed and colleagues found a much weaker familial 
association (Bradley, 2009) and Bailey-Wilson et al. (1993) concluded that purely 
genetic (either Mendelian dominant or recessive) or environmental hypotheses could 
be rejected. Instead, they suggested a two allele major locus hypothesis coupled with 
an unidentified environmental exposure. A significantly increased risk of developing 
ALS or PD among parents, siblings and surprisingly, spouses of patients (but not 
among relatives of controls), was demonstrated. Offspring of patients showed no 
increased risk (Plato et al. 1986). Additionally, genetically identical Chamarros on the 
island of Saipan, only 80 miles away, did not have ALS/PDC (Ince and Codd, 2005) 
and the disease appeared in a genetically divergent population of Filipino migrants to 
Guam after several years of exposure.  
 
In a 1981 study, Gajdusek et al. reported finding nine cases of ALS and two 
cases of PDC in Filipino migrants to Guam and ten cases of ALS and six of PDC in 
part-Filipino patients born on Guam. They had spent an average of 17 years on 
Guam before the onset of the disease. Of the four cases autopsied, the findings were 
somewhat equivocal: two showed changes consistent with Guamanian ALS but two 
showed only the classical pathology of sporadic ALS. It was determined that Filipinos 
had a rate of developing ALS that was six times that of the continental USA but still 
only 50% the rate of Chamarros living on Guam. The second generation of Filipino 
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migrants did not have a higher risk of developing neurodegenerative disease. Also, it 
was found that Chamarros who moved to California after at least 18 years of 
exposure to Guam maintained an elevated risk (four times the rate of US citizens) for 
over three decades but their children showed no increased risk (Ince and Codd, 
2005). These findings, supplemented by reports of a rapidly declining disease 
incidence, pointed towards the role of an environmental exposure.  
 
However, in 2005 the first evidence for a genetic component came from 
Hermosura et al. who reported a mutation in the transient receptor potential 
melastatin 7 membrane channel in a subset of Guam ALS/PDC patients. The 
channel is involved in intracellular calcium and magnesium regulation. A subsequent 
study implicated TRPM2 (Hermosura and Garruto, 2007). TRPM7 mutations were 
not found in ALS/PDC cases in the Kii peninsula (Hara et al., 2010) ruling out the 
mutation as the putative cause. Lynch et al. (2008) presented a gene-environment 
model, that showed significantly increased risk associated with a group of eight 
variables (age and gender, village, NFTs, metals, β-Methylamino-L-Alanine (BMAA), 
TRMP7 mutation, family history, somatic Lipoprotein Signal Peptide (LSP) mutation) 
in which genetic susceptibility combines with an environmental exposure or 
exposures in order to produce the disease. The most recent genetic study on the 
subject (Steele et al., 2015), found only 20% of patients had any identifiable 
pathogenic mutations, again confirming the relevance of environmental factors. 
 
In response to reports of a rapidly declining incidence of ALS/PDC, Plato et al. 
(2003) published a report that attempted to identify all cases of ALS and PDC 
reported on Guam between 1940-1999 in order to determine whether the reported 
changes in incidence rates, age at onset, sex ratio, and duration of the disease were 
accurate. They identified a total of 929 ALS/PDC cases. Of these, 436 (278 males 
and 158 females) were diagnosed as ALS and 493 (312 males and 181 females) 
diagnosed as PDC. They established that the incidence of ALS peaked in both males 
in females in 1950-54. Starting in the late 1950s, the incidence declined steadily until 
1980-84 when the rates were 4-5/100000. The incidence of PDC in males peaked in 
1960-64 and declined until 1980-84 and then increased slightly. PDC in females 
increased until 1970-74 and then declined sharply until 1980-84. After 1980, ALS 
incidence stabilized at 3/100000 and PDC increased to 18-19/100000.   
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Figure 6-1 Incidence of ALS and PDC on Guam from 1940-1999 
Reprinted by permission from Oxford University Press: Plato CC
1
, Garruto RM, Galasko D, Craig UK, Plato M, 
Gamst A, Torres JM, Wiederholt W. Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: 
changing incidence rates during the past 60 years. Am J Epidemiol. 2003 Jan 15;157(2):149-57. 
 
While the incidence has seemingly declined drastically, some authors report a 
continued high incidence. An island wide survey of Chamarros aged 65 and above 
was carried out, in which a high prevalence of dementia was identified (Steele and 
McGreer 2008). This indicates that the disease may have again changed 
phenotypes, possibly due to decreased exposure to the causative agent. As it is 
highly implausible that a gene could have been removed from a population in such a 
short period, especially within a relatively stable genetic group, searches for an 
environmental cause became a focus of future investigations. Environmental factors 
on Guam had changed rapidly because of modernization and westernization. 
Changes in residence, housing, nutrition, water supply and toxic exposures all 
occurred and could possibly have accounted for the decrease in exposure to the 
source of the disease (Plato et al., 2003). In a cohort study, Reed et al. (1987) found 
that of 23 variables, only preference for traditional Chamarro food was associated 
with increased risk. Two other case control studies, conducted by Reed and Brody, 
identified “growing up on farms, frequent contact with animals, and eating home-
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grown food as well as raw fish all together were significantly associated with PDC” 
(Caparros-Lefebvre and Steele 2005).   
 
The results of the epidemiological studies discussed above suggested an 
environmental toxin with a long latency period. The search for this toxin divided into 
two major lines of research: organic toxins and inorganic toxins. The indigenous 
cycad was identified early by locals as a likely cause, and put forward by Whiting as 
a hypothesis in 1963. Chamarros knew it was toxic and employed special measures 
to render it suitable for consumption. Researchers that sought an inorganic toxin 
focused their attention on a hypothesis related to an imbalance in water mineral 
content. They thought that such an imbalance may cause parathyroid dysfunction, 
which by affecting calcium and magnesium metabolism, would lead to increased 
uptake of heavy metals and eventual neurodegeneration (Garruto et al., 1990). There 
was also a handful of researchers that looked into the possibility of an unidentified 
slow viral agent given the similarity of the neuropathological findings those to 
postencephalitic parkinsonism (Spencer et al., 2016). However, attempts by 
Gajdusek to transfect the disease from human to monkey were unsuccessful and led 
to the abandonment of the infectious hypothesis (Spencer et al., 2016).    
 
6.1.2 The Cycad Hypothesis 
The cycad hypothesis was originally put forth by Marjorie Whiting in 1963 
(Steele and McGreer, 2008). Cycads are gymnosperms considered to be living 
fossils because they have been present since the Mesozoic era. There are 185 
species described, most of which are endemic. They are frequently cultivated as 
exotic ornamentals and also provide food for humans, particularly during times of 
famine. Cycads synthesize and store a number of toxic active ingredients including 
Methylazoxymethanol (MAM), cycasin, sterol glucosides, macrozamin, neocycasin 
and BMAA. Botanist Knut Norstog observed that cycads endemic to Guam produce 
pollen with particularly high concentrations of cycasin and BMAA and hypothesized 
an aerosolized route of exposure. Cycad seeds had been recognized to be 
poisonous and Chamarro people went to great lengths to remove the toxins. They cut 
open the seed and removed the gametophyte, which they then split, sliced or grated 
before soaking in at least three changes of water over several days (Banack and 
Murch, 2009). Three food items related to cycads in the traditional Chamarro diet 
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include: fadang (tortillas), fadang pilota (dumplings) and fanihi (flying foxes). In 2007, 
a group of biostatisticians led by Borenstein conducted an in depth population study 
of the Chamarro people, statistically showing that picking, processing or eating 
fadang in young adulthood presents the highest associated risk of developing 
ALS/PDC (Borenstein et al., 2007. They did not find a significant relation to the 
consumption of flying foxes. In support of  this hypothesis it was found that the 
marked decrease in the incidence of ALS/PDC in Guam paralleled the decreased 
use of cycad flour and the near extinction of fruit bats (Bradley and Mash 2009). 
Studies have implicated several toxins (discussed in the next chapter) in cycads as 
potential causes of ALS/PDC but due to a lack of success in producing an animal 
model, all remain unproven. 
 
 
 
Figure 6-2: Cycads and Fruit Bats on Guam 
Reprinted by permission from John Wiley and Sons: Steele, JC. Parkinsonism-Dementia Complex of Guam. 
Movement Disorders 2005; Vol.20: Suppl. 12, pp S99-S107. 
 
 
6.1.3 Cycad Toxins 
6.1.3.1 L-BOAA 
It is present in C. circinalis and decreases mitochondrial enzymatic activity and 
elicits marked inhibition of mitochondrial complex I. It has a strong affinity for 
glutamate receptors, especially α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic 
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Acid (AMPA) receptors, making it excitotoxic. Data indicates that it produces 
vacuolization, axon and dendrite swelling in neurons in the thalamus, and to a lesser 
extent, in the hippocampus, cortex, and cerebellum (Ross, 1989). 
6.1.3.2 L-BMAA 
Following the discovery that Beta-Oxalylamino-L-Alanine (BOAA) was 
responsible for the upper motor neuron (UMN) disease lathyrism, researchers looked 
for BOAA in cycads and ended up discovering β-N-methylamino-L-alanine (BMAA) 
(Bradley and Mash 2009). BMAA is a non-protein amino acid with the molecular 
formula C4H10N2O2 and a molar mass of 118.13 g/mol. The naturally occurring 
isomer is L-BMAA (Vega, 1968). Non-protein amino acids are potent toxins that help 
plants to protect themselves against predation and function as nitrogen storage 
molecules (Bradley and Mash, 2009). 
 
In the 1980’s, Spencer et al. demonstrated that administering 100-315 mg 
BMAA/kg daily for twelve weeks to macaques caused symptoms very similar to 
ALS/PDC. It was the first successful in vivo experiment involving primates, but the 
animals demonstrated only acute/subacute, reversible toxicity and not the chronic 
form characteristic of Guamanian ALS/PDC (Bradley 2009). Duncan and colleagues 
rejected the BMAA hypothesis because they found extremely low concentrations of 
BMAA in their own experiments. Moreover, they reported that the dose used in 
Spencer’s experiments was orders of magnitude higher than humans would be likely 
to ingest from flour. They calculated the worst-case daily exposure to be 0.36 mg/kg  
and cumulative exposure to be 10.8 mg/kg BMAA per kilogram of bodyweight per 
month (Duncan et al., 1990).  
 
The BMAA hypothesis was revived when Cox et al. demonstrated that the 
traditional diet of Chamorros contained high levels of BMAA through consumption of 
fruit bats (3 mg per gram of meat, 3 mg per 250 mL of broth), cycad flour, and 
possibly the meat of pigs and other animals that forage on cycad seeds (Bradley, 
2009). Flying foxes had commonly been eaten by indigenous people on ceremonial 
occasions (Cox and Sacks 2002). The local custom was to cook the bats by boiling 
them in their entirety in coconut milk (Ince and Codd, 2005). This was identified as a 
core part of Chamarro culture, particularly in the villages of Umatac and Inarajan 
which, had the highest incidence of ALS/PDC. Furthermore, the greater frequency of 
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bat consumption by men corresponded to the higher rate of ALS/PDC in the male 
population.  
 
Two species of flying foxes, Pteropus tokudae and P. mariannus were at one 
time very common on Guam. They were known to consume up to 2.5 times their 
body weight in fruit and nectar from cycads each night, and like all bats, accumulate 
lipophilic toxins in their fat. Analysis of museum bat specimens showed a mean 
concentration of 3,556 g BMAA/g (Cox et al., 2002). In 1900, Guam had more than 
50,000 bats and by 1958 the number had declined to 3000. The decline in population 
resulted from their popularity as a food substance combined with greater access to 
firearms in the 20th century. P. tokudae was hunted into extinction by 1978 and P. 
mariannus reduced to less than 100 animals by 1974 (Cox and Sacks, 2002). 
It was calculated that a human of 70 kg eating two fruit bats of 500 g each 
would ingest 28 mg/kg of BMAA per kilogram of bodyweight (Cox and Sacks, 2002). 
In other words, the dose of BMAA from eating one bat would be equivalent to 
consuming about 1014 kg of cycad flour (Ince and Codd, 2005), which happened to 
be close to the doses used in Spencer’s experiments on macaques. Unfortunately, 
subsequent in vivo studies in which mice were orally dosed for periods of eleven 
weeks or 30 days showed no change in behavioral, neurochemical, or 
neuropathological findings (Al-Sammak et al. 2015).    
 
The BMAA hypothesis gained momentum for a third time as a result of studies 
by Cox and colleagues (2003) when they found that BMAA originates from symbiotic 
cyanobacteria resident in specialized coralloid roots of Cycas micronesica (37 g/g) 
and proceeded to provide a mechanism for biomagnification in ascending trophic 
levels of the Guam ecosystem. Subsequent studies identified that more than 95% of 
cyanobacterial species produce BMAA (0.3 g BMAA/g) (Ince and Codd, 2005), 
which then accumulates in cycads. The cycad seed sarcotesta was found to contain 
9 g BMAA/g and the outer skin of the sarcotesta contains 50 times that of the roots 
(Ince and Codd, 2005).  Cycad seeds are then eaten by flying foxes (3556 g/g 
BMAA) and eventually through consumption of the foxes, reach the Chamarro 
people. Each organismic level is associated with an increase of two orders of 
magnitude in BMAA concentration (Cox et al., 2003).  
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Figure 6-3 Biomagnification of BMAA 
Susan J. Murch et al. PNAS 2004;101:12228-12231 
 
 
In support of the BMAA bioaccumulation theory, Banack et al. (2010a) found a 
significant link between consumption of foxes and disease status, especially in those 
individuals who reported consumption of moderate to high numbers of fruit bats.  
Banack, Cox, and Murch then analysed hair samples to determine exposure to 
BMAA and whether it correlated with clinical symptoms. While BMAA was detected in 
the hair of villagers who had consumed flying foxes, cycads, pigs, deer or land crabs, 
the presence of BMAA in hair was not directly correlated to symptoms of disease 
(Banack et al., 2010a). BMAA was not present in the hair of the control group (non-
consumers of flying foxes etc.).  The presence of  BMAA in the hair of villagers who 
consumed one of the proposed BMAA- containing foods did indicate some level of 
exposure but clinical symptoms would not likely be present for several years (Banack 
et al., 2010a).   
 
6.1.3.2.1 Protein-bound BMAA 
 
While early experiments had only measured free BMAA concentration, it was 
discovered that BMAA occurs at much higher levels in the protein fraction of cycad 
flour than in the free form (Bradley and Mash 2009).  Murch et al. (2004) showed that 
the brains of Chamarro people dying of ALS/PDC contain protein bound BMAA an 
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average of 100 (10-240) times the concentration of the free form. They found that the 
brains of all autopsied ALS/PDC patients contained BMAA (five out of six contained 
free BMAA and six out of six contained protein bound BMAA at concentrations 
ranging from 0.8-5 mM). In addition to demonstrating a larger accumulation of BMAA 
than had been previously measured, it indicated that one possible mechanism of 
BMAA toxicity is through its misincorporation into proteins.  
 
Misincorporation of BMAA into proteins could account for the long latency 
period between toxin exposure and disease onset. Murch and colleagues (2004) 
proposed that an endotoxic BMAA reservoir must be present.  Pharmacokinetic 
studies in rats have shown that only 10% of BMAA is excreted into urine and feces 
and the fate of 90% of the BMAA is unknown. Murch et al. (2004) hypothesized that 
low dose, long term exposure leads to BMAA accumulation in tissue proteins and 
that, as proteins are slowly catabolized, the BMAA is released causing neurotoxicity. 
The peak incidence shortly after WWII may have resulted from starvation on the 
island of Guam during the Japanese occupation, which led to increased catabolism 
of protein with a marked increase in toxicity.  
 
 
Figure 6-4 Endotoxic Reservoir of BMAA. According to Susan J. Murch et al. PNAS 2004;101:12228-
12231 
 
 
One example of possible BMAA-protein misincorporation is related to melanin.  
BMAA has been shown to selectively bind to synthetic melanin and to melanin 
containing cells of the retina and brain of rats and mice. BMAA appears to be 
 14  
incorporated into melanin during synthesis and may be linked to the degeneration of 
the substantia nigra in PD. This, combined with the retinal toxicity of BMAA suggest a 
BMAA link between PDC and pigmentary retinopathy (Bradley, 2009), an unusual 
retinopathy that occured in 52% of Guamanian ALS/PDC patients (compared with 
only 16% of controls) (Cox et al., 1989). Steele and collaborators (2015) carried out a 
prospective study over twenty years that followed 239 Guamanian Chamarros in 
order to assess whether there is an association between linear pigmentary 
retinopathy and ALS/PDC. They found that of the patients who had been diagnosed 
with this retinopathy, 30% developed ALS/PDC (versus 2% of those without 
pigmentary retinopathy). Pigmentary retinopathy has also been seen in cases of 
ALS/PDC on the Kii Peninsula and may mark the etiologic event (Ludolph et al., 
2009). Interestingly, the genetic variant first connected with ALS/PDC (Transient 
Receptor Potential Cation Channel, Subfamily M) was originally described in 
connection with metastatic melanomas (Banack and Murch, 2009). Identification of 
the cause of this retinopathy could provide insight into the pathogenesis of ALS/PDC 
on Guam and elsewhere. 
 
6.1.3.2.2 Animal model of chronic BMAA toxicity 
Cox et al. (2016) recently reported the first successful chronic BMAA toxicity 
animal model. Anti-tau antibody AT8 (to pSer202 and Thr205) positive tangles and 
neuronal processes as well as sparse -amyloid plaque–like deposits were observed 
in the brain tissues of vervets dosed with BMAA. The NFT were found in the 
perirhinal, entorhinal, motor, frontal, temporopolar and occipital cortices as well as 
the amygdala. However, no inclusions were seen in the hippocampus. The lack of 
NFT in the hippocampus could possibly be accounted for by differential neuronal 
sensitivity to glutamate excitotoxicity. In the replication experiment, chronic BMAA 
exposure over 140 days again led to hyperphosphorylated tau deposits and NFT 
formation in all BMAA-fed vervets. There was a clear dose-response relationship 
between dietary exposure and density of NFTs. Even with low dose cohorts, protein 
bound BMAA within vervet brain tissues reached concentrations consistent with the 
Guam disease. The distribution of NFT and their relationship to dose exposure in the 
temporal lobe is similar to Braak 1 early stage AD pathology.  That is to say, a high 
density of NFT was observed in the transentorhinal region and no profound clinical 
symptoms were  observed in any of the vervets. This is similar to Braak I early stage 
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AD pathology in which the pathological changes are largely confined to the pre-alpha 
layer of the transentorhinal region and there are no cognitive symptoms because the 
threshold of brain changes required to cause symptoms has not yet been reached 
(Braak and Braak, 1995).  
 
6.1.3.2.3 BMAA hypothesis controversy 
Opponents of the BMAA hypothesis question the relevance of the findings on 
several grounds. Firstly, the result of BMAA content analysis in cycad flour was found 
to be similar in both high and low prevalence villages (Duncan, 1990). Snyder and 
Marler questioned the foundation of the cyanobacterial biomagnification hypothesis 
when they found that BMAA may be produced by cycads without cyanobacteria 
(Snyder and Marler 2010). Additionally, some authors have reportedly been unable to 
detect any free or protein bound BMAA in the brains of either Chamarros or controls 
(Montine et al. 2005; Snyder et al., 2009). On the other hand, a comprehensive 
review of animal models of BMAA neurotoxicity by Karamyan and Speth (2008) 
found that the results of almost all in vivo BMAA studies proved its neurotoxicity in 
regards to its effects on motor neuron function. Several studies have shown 
neurotoxicity involving hyperexcitability, inability to extend legs, dragging gait, 
myoclonus and convulsions after a single dose, administered in animal models, 
intraperitoneally, orally, and intracerebroventricularly (Al-Sammak, 2015).  The sum 
of the evidence suggests that BMAA is at least partially responsible in the case of 
ALS/PDC.  
 
6.1.3.2.4 Pharmacokinetics 
After being consumed orally, 80% of ingested BMAA passes from the gut into 
the blood stream. It then crosses the BBB either by facilitated diffusion or transport 
by a specific transporter, ie. LAT1 (Boado et al., 1999).  Several studies have 
demonstrated poor uptake of BMAA into the adult rodent brain (Duncan 1991; Smith 
1992; Karlsson 2009; Xie, 2013) but high uptake into various brain regions in 
fetal/neonatal mice. This correlates well with epidemiologic data suggesting that the 
toxic exposure occurs in childhood. Mash and colleagues recently showed that the 
uptake of L-BMAA into the brain differed considerably from that of other tissues. In 
the brain, the maximum concentration was found to occur around seven hours after 
ingestion, compared to 0.5-2 hours for muscle, heart liver and kidney. Moreover, the 
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half-life of BMAA in the brain was longer (25 h) compared to other organs (10-15 
hours). The BMAA was preferentially taken up in the hippocampus, basal ganglia and 
cerebellum of rats (Bradley and Mash 2009).  Al-Sammak et al.  (2015) observed that 
the median lethal dose in mice was 3 mg/kg body weight and the lowest observed 
effect level was 2 mg/kg body weight. Histopathologic lesions were not seen in 
brains, suggesting a biochemical lesion.  
 
6.1.3.2.5 Proposed Mechanisms of Toxicity 
BMAA is believed to exert its effects through multiple mechanisms including 
excitotoxicity via glutamate receptors, oxidative stress and protein 
misincorporation.  The multiple mechanisms of action could be responsible for 
the wide variety of disease phenotypes.     
 
o The glutamate hypothesis 
Shortly after the isolation of BMAA from cycads, it was shown to 
have neurotoxic and neuroexcitatory properties (Polsky et al., 1972). As 
glutamate is the main excitatory neurotransmitter in the CNS, and there 
was a postulated link between glutamate and sporadic cases of ALS 
(patients had shown elevated levels of plasma and CSF glutamate 
levels), several studies were performed in an attempt to determine the 
effect of BMAA on glutamate receptors. In general, excitatory toxicity 
results from exposure to excitatory amino acids (glutamate and 
aspartate) stimulating glutamate N-Methyl-D-Aspartate (NMDA) 
receptors, thereby causing excessive intracellular calcium ion 
accumulation and motor neuron death (Bradley and Mash, 2009). 
Unlike other excitatory amino acids (EAAs), BMAA lacks a 
characteristic terminal side-chain acidic moiety important for potential 
excitatory toxicity, which prompted the suggestion that its effects may 
be indirect (Vyas and Weiss, 2009). Neuronal depolarization by BMAA 
has been shown to be bicarbonate dependent through 
electrophysiological studies (Vyas and Weiss, 2009). Physiologic 
bicarbonate ions react with BMAA in a covalent reaction between CO2 
and an unprotonated amino group that results in the formation of a 
carbamate (Vyas and Weiss, 2009). This carbamate shares a structural 
similarity to glutamate and is likely to be the toxic agent since BMAA is 
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toxic only in the presence of bicarbonate (Bradley and Mash, 2009).  In 
this form, BMAA competes for binding at various types of glutamate 
receptors.  Binding of the carbamate then leads to shifts in ion 
concentration involving an increase in intracellular sodium and calcium 
and a decrease in potassium.  Increases in intracellular calcium disrupt 
mitochondrial function leading to release of ROS.  Cytochrome–c is 
then released from mitochondria leading to apoptosis (Chiu, 2011). 
 
 
Figure 6-5: BMAA reacts with bicarbonate to form a -carbamate that may simulate 
glutamate 
 Weiss JH. BMAA--an unusual cyanobacterial neurotoxin. Amyotroph Lateral Scler. 2009;10 Suppl 2:50-5. doi: 
10.3109/17482960903268742. 
 
 
 
BMAA causes changes in cholinergic and glutamatergic transmission 
due to a decrease in glutamatergic receptors. Experiments in rats 
shows that BMAA affects the monoaminergic neurons in the substantia 
nigra, increases the output of dopamine and decreases noradrenaline 
levels in the hypothalamus. BMAA also inhibits 3h-glutamate binding to 
metabotropic and strychnine-insensitive 3H-glycine binding site. It 
strongly stimulates polyphosphoinositol hydrolysis through a 
mechanism involving metabotropic receptors (Bradley and Mash 2009). 
Insight into the mechanisms of BMAA toxicity has been achieved 
through experiments utilizing antagonists of various glutamate 
receptors.  BMAA has been shown to be a weak agonist at NMDA 
receptors requiring milimolar concentrations for lethal effects on 
neurons (Vyas and Weiss, 2009). Concentrations of 3mM cause the 
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death of entire cortical neuron populations but widespread 
neurodegeneration induced by BMAA is largely blocked (80%) by  
selective NMDA antagonists (Weiss 1989).  Spinal motor neurons 
appear to be especially sensitive to BMAA.  Mouse spinal neurons 
show specific toxicity at doses as low as 30 M (Liu 2010).  BMAA 
produces postsynaptic vacuolization and neuron death that can be 
prevented by NMDA receptor antagonists and open-channel blockers 
(Bradley and Mash 2009). The acute convulsant effects of BMAA can 
be attenuated by antagonists of both NMDA and AMPA receptors for 
glutamate.  
 
o Oxidative Stress 
Closely intertwined with excitatory toxicity is increased oxidative 
stress. Nunn and Ponnusamy postulated that BMAA toxicity might be 
due to its conversion to methylamine, which increases oxidative stress, 
lowers free pyidozal-5’-phosphate and causes selective depletion of AA 
from brain cells (Bradley and Mash 2009). Additionally, dimers or 
polymers of BMAA have the ability to chelate metal ions from solution 
resulting in the formation of reactive oxygen species (ROS). Couratier 
et al. suggested that neuronal degeneration in ALS could be initiated at 
the level of glutamate-kainate receptors and is possibly due to a 
combination of direct action on NMDA receptors and activation of 
mGluR5 and/or oxidative stress induction (Couratier et al., 1993). 
Studies have demonstrated that BMAA (3mM, 3h) inhibits the 
cysteine/glutamate antiporter that mediates cysteine uptake, leading to 
a depletion of glutathionine thereby increasing oxidative stress (Liu et 
al., 2009). It also activates AMPA-kainate receptors causing the 
selective death of motor (cholinergic) neurons.  Concentrations as low 
as 30 M cause motor neuron death and concentrations of 10 M 
enhance neuronal death in a synergistic manner (Liu et al., 2010). 
Chronic infusion of blockers of calcium-permeable AMPA channels 
markedly reduced the loss of spinal motor neurons in rats. Low BMAA 
exposures trigger selective neuronal injury via AMPA/kainate receptors, 
which can be blocked by a broad spectrum of glutamate blockers, thus 
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strengthening the feasibility of the BMAA hypothesis because toxicity 
occurs at low levels (Vyas and Weiss, 2009). 
 
o Misincorporation into proteins 
Due to the structural similarity to the amino acid alanine, it has been 
hypothesized that the misincorporation of BMAA into brain proteins 
leads to protein misfolding or conformational change (Banack et al. 
2010). Dunlop et al. (2013) showed evidence that BMAA competes with 
L-Serine for protein synthesis in mammalian cells in culture resulting in 
apoptotic cell death and providing a possible mechanism to explain why 
in some tissues, BMAA is mostly “protein associated” and can only be 
released by hydrolysis or proteolysis. Karlsson et al. showed that 
BMAA was distributed to all brain areas in neonatal rats and was also 
associated with proteins, especially in the hippocampus (Karlsson, 
2015). Okle et al. studied the non-excitotoxic effects of low BMAA 
concentrations using neuroblastoma cells lacking a NMDA receptor and 
found a close association between BMAA and proteins but were unable 
to confirm misincorporation. They concluded that there are two 
independent mechanisms of toxicity according to the dose of BMAA 
used: high dose (≥ 1mM, 48 h) excitotoxicity leads to increased ROS 
and protein oxidation, while a low dose (≥ 0.1 mM, 48 h) of BMAA leads 
to a dysregulation of protein homeostasis with resultant ER stress. This 
correlates with the report of Spencer et al. (1987), who observed more 
than one mechanism of toxicity in macaques: early (2-12 weeks) motor 
toxicity after a high dose of BMAA and late (>13 weeks) behavioural 
change and extrapyramidal signs after smaller doses. Misincorporation 
of BMAA into proteins provides a mechanism in which BMAA could 
initiate misfolding, which could lead to the accumulation of aggregate-
prone proteins in neurons (Main et al., 2016).   
 
o ER stress 
The accumulation of misfolded proteins in the ER causes ER 
stress within cells; the mechanisms that deal with this stress are known 
as the unfolded protein response (UPR) (Main et al., 2016). Current 
data strongly suggest that the ubiquitin proteasome system (UPS) plays 
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a central role in the clearance of abnormally folded and oxidized 
proteins. Failure of the UPS or protein structural changes via ROS 
damage can lead to the inability of neuronal cells to degrade 
ubiquinated proteins, contributing to the formation of inclusions and 
neurodegneration (Okle, 2013). Interestingly, tau itself has been linked 
with impairment of the UPS (through inhibition of HDAC6) (Šimić et al., 
2016). Okle et al. (2013) noted that low dose BMAA (≥0.1 mM, 48 h) 
increased protein oxidation, ubiquination, 20S proteasomal and 
caspase 12 activity, expression of the ER stress marker CHIP, and 
enhanced phosphorylation of elf2a protein. On a similar note, Main et 
al. showed that BMAA at low levels (0.5 mM, 24-48 h) does not cause 
an acute toxicity in neuroblastoma cells but it does increase the 
expression of the ER stress marker, C/EBP homologous protein 
(CHOP) and increases the activity of the pro-apoptotic enzyme 
caspase-3. They also observed an increase in the activity of the 
lysosomal cysteine proteases cathepsin B and L, which are markers of 
the accumulation of proteins in the lysosomal system. Interestingly, 
they were able to prevent the proteotoxic effects using co-treatment 
with L-serine, implying that the proteotoxic changes initially resulted 
from incorporation of BMAA into proteins (Main et al., 2016). 
 
 
Figure 6-6: Mechanism of BMAA toxicity 
Chiu, AS., Gehringer, MM., Welch, JH., Neilan, BA. Does -Amino- -methylaminopropionic acid (BMAA) play a 
role in neurodegeneration? Int. J, Environ. Res. Public Health 2011; 8:3728-3746. 
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6.1.3.2.6 BMAA effects on Tau 
Only one study to date has focused exclusively on the effects of BMAA 
on tau protein. Arif et al. identified a decrease in PP2A activity associated with 
an increase in inhibitory phosphorylation of its catalytic subunit PP2Ac at Tyr 
307 and abnormal hyperphosphorylation of tau in brains of patients with 
ALS/PDC.  Subsequent studies have been performed to determine the effect 
of BMAA on PP2A activity in mouse primary neuronal cultures and 
metabolically active rat brain slices. The results showed that BMAA 
significantly decreased PP2A activity, leading to an increase in tau kinase 
activity resulting in tau hyperphosphorylation at PP2A favourable sites. By 
blocking the mGluR5 receptor and Src, the abnormal phosphorylation of tau is 
prevented. It was shown by co-immunoprecipitation that BMAA dissociates 
PP2Ax from mGluR5 making it available for phosphorylation at Tyr307 by Src 
(Arif et al., 2013). 
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Figure 6-7 BMAA effect on tau proteins. 
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 Relevance beyond the Western Pacific? 
Cyanobacteria are ubiquitous and potential exists for widespread 
human exposure through aerosolization and biomagnification in the food 
chain. BMAA has been detected in many fish species and aquatic plants as 
well as open water indicating possible human exposure (Al-Sammak, 2015). 
Interestingly, cyanobacteria have been found in the human gut and although 
they are usually a small component, an imbalance could have possible 
relevance for developing neurodegenerative disease (Brenner, 2012; 
Klingelhoefer and Reichmann, 2015 ; Ley et al. 2006). 
In support of the hypothesis regarding possible global implications of 
cyanobacterially-produced BMAA, a cluster of ALS with an incidence about 25 
times higher than the expected rate in the USA was recently identified around 
a lake in New Hampshire and is hypothesized to be the result of 
cyanobacterial blooms that produce BMAA (Banack, 2015).  Banack and 
colleagues tested carp brain, muscle, and liver as well as filtered aerosol for 
BMAA and demonstrated a positive result and thus possible cause for 
sporadic ALS. This supported earlier findings in which brains of two Canadian 
AD patients from the Vancouver brain back tested positive for BMAA at similar 
concentrations to those found in Chamarros (Murch et al., 2004). Pablo and 
Mash confirmed and expanded on these findings through their studies on 
brains from Miami with proven ALS/AD. They found BMAA in the protein 
fraction in 49/50 AD/ALS brains at a similar level reported by Murch et al. and 
importantly, no BMAA in controls (Chiu et al., 2011). Mash and colleagues 
also performed studies on the brains of Parkinson’s disease patients and 
found levels of BMAA similar to those found in previously autopsied ALS/AD. 
These studies prove exposure to BMAA exists outside the Western Pacific foci 
and provides a possible etiologic link to sporadic neurodegenerative disease. 
Interestingly, a two fold increase in the incidence of ALS in deployed 
US military involved in several wars has been identified raising the question of 
whether BMAA is present in the dust of cyanobacterial- containing desert crust 
(Bradley and Mash, 2009). Additionally, studies have reported the coexistence 
of ALS and PDC in 4 patients in the Czech Republic (Farnikova et al., 2010) 
as well as a six fold increased incidence of ALS in Italian soccer players, 
prompting questions about sporadic, genetic, or possibly similar environmental 
exposures to BMAA outside of the Western Pacific. It could be informative to 
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conduct research on possible cyanobacterial/BMAA sources in all of these 
cases.    
 
6.1.3.3 Sterol Glucosides 
Among the opponents to the BMAA hypothesis are Shaw and colleagues who 
showed that pure BMAA fed to mice over 30 days caused no sign of toxicity (Shaw et 
al., 2009). A combination of the knowledge that Chamarros were aware of the toxicity 
of cycads and carefully washed the seeds to detoxify them as well as findings that 
BMAA content of the flour was the same in high and low prevalence villages led 
Shaw and colleagues to search for water insoluble toxins. They identified a new 
group of neurotoxins in cycad seeds through chemical extraction of washed cycad 
flour. Three primary -D-glucosides were isolated that showed neurotoxic effects in 
vitro: β-Sitosterol β-d-Glucoside (BSSG) (the most abundant but least potent 
neurotoxin), campesterol and stigmasterol (SG) (Shaw et al., 2009).  They observed 
that mice exposed to BSSG and SG on a daily basis for 15 weeks developed a 
pattern of toxicity similar to that found in ALS/PDC, which included progressive 
deficits in motor, cognitive, and olfactory functions, neuron loss in the spinal cord, 
nigrostriatal system, cortex, hippocampus, and olfactory bulb. 
Sterol glucosides occur in many plants and animals and it has been 
hypothesized that autosynthesis, H. pylori, mycoplasma and other bacteria are 
additional possible sources of exposure.  Especially interesting on a global scale is a 
possible link between H. pylori and parkinsonism. Schultz et al. (2006) hypothesized 
that cholesterol glucosides arising from H. pylori infection may act as neurotoxins, 
promoting the degeneration of DAergic neurons, in a similar fashion to that thought to 
link cycad consumption and ALS-PDC.  
Several authors including Karamyan, Speth, and Spencer criticized the sterol 
glucoside hypothesis because glucosides are normally present in high concentrations 
in the ordinary human diet.  Moreover, some of them have been marketed as health 
supplements (Bradley, 2009). Shaw and colleagues believe that, since cycads 
contain a higher amount of sterol glucosides than most other plants, it is a dose-
related toxicity.  Additional criticism involves the inability to remove both cycasin and 
protein bound BMAA by the methods Shaw and colleagues employed for washing 
the cycad flour.   
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6.1.3.4 Cycasin 
Cycasin is a member of a family of naturally occurring azoxyglycosides and is 
the most abundant toxin by weight in Cycad (4% w/w). It has been shown to be a 
weak cyanogen compound that releases minor amounts of hydrogen cyanide 
following hydrolysis by -glucosidases in the alkaline environment of the small 
intestines. The active toxic metabolite is the potent alkylating agent MAM. Most of the 
MAM formed by this reaction is degraded to nitrogen gas, methanol and 
formaldehyde, particularly in the acidic conditions of the stomach (Barceloux, 2009). 
Samples of cycad flour tested in Guam contained 10 times more cycasin than BMAA 
on average and those samples containing the highest cycasin content correlated with 
high prevalence villages (Kisby, 1992).   Spencer et al. (2016) suggest that perhaps 
by acting as a slow toxin, cycasin is the main causative agent of ALS/PDC, with 
BMAA playing an agonistic role.  
 
  Support for this hypothesis has been demonstrated by the occurrence of 
pathological changes comparable to ALS/PDC after administration of MAM to 
neonatal mice. MAM disrupts neuronal migration in the developing rodent brain 
resulting in ectopic neurons in the cerebellum, which are similar to those found in 
some ALS/PDC patients (Spencer, 2016). Proteomic studies show that a single 
injection of MAM produces persistent DNA damage, and disrupts the expression of 
proteins and genes that regulate the neuronal cytoskeleton, protein degradation, and 
mitochondrial function. It appears that MAM targets distinct networks in the 
developing brain and that the adult brain is relatively insensitive to its effects 
(Spencer et al., 2015). Another possible link between cycasin and ALS/PDC is 
related to its effects on pancreatic islet cells. MAM damages human islet cells, which 
is consistent with the 44% incidence of diabetes amongst ALS/PDC patients on 
Guam (Spencer et al., 2016).  
 
Cycasin and MAM readily cross the BBB through a Na+-dependent glucose 
transporter (SGLT) (Spencer et al., 2015). MAM produces DNA damage by 
methylation leading to N7-mG and O6-mG DNA lesions. The immature human brain 
has a low capacity to repair alkylation-induced DNA damage. DNA lesions cause 
changes in typically “cancer associated” genes such as P53 perhaps indicating that 
modulation of those genes can cause conditions other than cancer in non-cycling 
cells. Spencer (2016) hypothesizes that persistence of O6-mG DNA lesions can lead 
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to changes in the CNS that result in a predisposition to neurodegenerative disease 
later in life. DNA damage or epigenetic-mediated mechanisms are thought to 
contribute to tau pathology through the ability of MAM to induce latent tau 
phosphorylation in mice. It has been demonstrated that MAM increases glutamate-
stimulated MAPT mRNA expression and cell loss in vitro. As part of an increased 
transcription response, increased MAPK and caspase-3 activity have been noted, 
both of which have been documented to be involved in tau aggregation and NFT 
formation. In studies by Kisby et al. (2011), a single dose of MAM produced early 
DNA damage, followed by an increase in cortical and hippocampal levels of tau 
isoforms, tau oligomers and phospho-tau species 3 months later. Moreover, the 
pathology was preceded by early changes in brain cell signaling proteins, PI3 kinase, 
phospho-Akt, and GSK-3  (Kisby et al., 2011).  Moreover,  MAM caused the 
increased presence of genes associated with olfaction, possibly accounting for the 
change in olfaction status that is one of the earliest signs of many types of 
neurodegenerative disease (Spencer et al., 2016; Klingelhoefer and Reichmann, 
2015).   
 
MAM is tumorigenic in the periphery, particularly to the intestines. The Wnt/ -
catenin signalling pathway appears to be common to perturbations of function in both 
brain tissue and colonic epithelium (Kisby et al., 2011). In a murine colon cancer 
model, the MAM treated mice display elevated -catenin levels and decreased 
activity of GSK3  (a multifunctional serine/threonine kinase that participates in 
insulin-dependent glycogen synthesis). Over expression of GSK3  resulting from 
age-related negative regulation of Wnt signalling promotes excessive tau 
phosphorylation in brain tissue, a key feature of pathological aging and AD (Spencer 
et al., 2016).  
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Figure 6-8: Proposed relationship between MAM-induced cancer and brain disease 
Kisby GE, Fry RC, Lasarev MR, Bammler TK, Beyer RP, Churchwell M, et al. The cycad genotoxin MAM 
modulates brain cellular pathways involved in neurodegenerative disease and cancer in a DNA damage-linked 
manner. PLoS ONE 2011; 6:20911; DOI:10.1371/journal.pone.0020911. 
 
6.1.3.5 Rotenone 
A hypothesis of neurotoxicity that has never been tested in Guam but could be 
linked with ALS/PDC involves exposure to the pesticide, rotenone. Rotenone is 
known to cause parkinsonism and for many centuries the Chamarros used plants 
containing this compound to paralyze fish and shrimp in rivers and ocean shallows. 
In the village of Umatac, which has the highest incidence of PDC, people remember 
pounding the roots and leaves of Derris elliptica and Derris trifoliate into a mash that 
they spread over the surface of the sea in a large area (Caparros-Lefebvre et al., 
2006). The use of this method of trapping fish ended shortly after WW II. It could be 
that exposure in the past caused ALS/PDC after a long latency. Support for this is 
given by Greenmyre and collaborators who developed a model of chronic toxicity 
after exposure (Greenmyre et al., 2001), and by the surveys of Filipino migrants who 
developed ALS/PDC and denied eating cycads but were heavy consumers of locally 
caught fish.   
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6.1.4 Inorganic Toxins 
The other major branch of research has involved a search for inorganic toxins. 
Studies by several different groups revealed the only environmental factor directly 
correlated with each of the three Western Pacific foci was a deficiency in calcium and 
magnesium in the drinking water, coupled with high levels of aluminium and iron. On 
Guam, the high incidence area is covered with a red-clay soil containing high levels 
of aluminium (40%), iron oxides (20%) and silica (1%) and similar foci exist in the 
other two areas (Garruto et al., 1990). The involvement of alkaline earth metals has 
been supported by findings that 20-46% of Guamanian and Kii Peninsular patients 
exhibited biochemical disturbances of calcium and vitamin D metabolism. Studies of 
Guamanian children and adults also suggested a lower bone mass in the general 
population (Garruto et al., 1990). This complements the findings of calcium, 
aluminium and silicon in the brain and spinal cord tissues from patients with 
ALS/PDC (Malette et al., 1977). Additionally, defects in calcium and vitamin D 
metabolism have been reported in sporadic cases of ALS. The deposition is 
hypothesized to interfere with axonal transport by disrupting the cytoskeleton and 
altering normal catabolism resulting in excessive accumulation of neurofilament. The 
deposition is likely to occur long before the onset of clinical symptoms.  
Taniguchi et al. (2013) reported cataleptic behavior in mice (equivalent to PD 
in humans) fed a low calcium/magnesium diet, which was transiently relieved by 
administration of L-DOPA and amantadine. It has been reported that accumulation of 
pollutant metals such as manganese and aluminium is likely caused by metabolic 
changes due to a lack of protective factors. A reduction in blood calcium levels has 
been found to enhance aluminium absorption and aluminium has been shown to 
cause lesions similar to those found in ALS/PDC. Exposure to arsenite was shown to 
result in a significant increase in the phosphorylation of several amino acid residues 
in tau. Arsenite induced tau phosphorylation did not however, involve glycogen 
synthase kinase-3 or protein phosphatase-1 or -2 (Giasson et al., 2002). 
 
Interestingly, extremely high levels of manganese have been found in 
Pandanus trees in Guam, a tree that once had a strong role in Chamarro culture as a 
source of food, fibre and medicine. Manganese has been suspected to play a role in 
ALS/PDC since 1965 (Denton et al., 2009). Normally, manganese is biologically 
unavailable in soil and rocks because of its 4+ valence, but under wetland conditions 
it may be reduced to Mn2+ and make its way into biological resources. Manganese 
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poisoning is symptomatically similar to PDC. Reported cases of manganism have 
been confined almost exclusively to occupational exposures involving inhalation of 
dust.  
 
6.1.5 Neuropathology of ALS/PDC 
On the basis of on the basis of NFT similarity and the coexistence of both 
phenotypes in 7% of cases, Hirano and Zimmerman reached the conclusion that the 
ALS/PDC syndromes represent a spectrum of a single disease. The intensity of 
NFTs was less in ALS than PDC and showed a typical anatomical distribution in the 
motor system but the cytopathology and molecular pathology were reportedly 
different from classical ALS. In ALS/PDC spinal cord NFT pathology is present both 
in anterior horn motor neurons and also in other areas of the spinal white matter 
including the dorsal horn (Ince and Codd, 2005). The tangles share the same profile 
of tau biochemistry as the lesions present in other brain regions. Some authors 
published papers showing that classical ALS pathology (non-tau ubiquitinated 
inclusions) is also a feature of Lytico (Ince and Codd, 2005). In a neuropathology 
study by Winton and colleagues (Winton et al., 2006) of nine PDC brains and eight 
Chamarro controls, widespread accumulations of insoluble, hyperphosphorylated tau 
similar to the PHF of AD were found throughout the gray and white matter. Western 
blot analysis showed widespread tau pathology in the neocortex, cerebellum and 
medulla that was confirmed by the identification of multiple types of tau-positive 
neuronal and glial inclusions using immunohistochemical methods. A high degree of 
tau pathology in the hippocampus and entorhinal cortex of controls was also 
detected. It differed from AD in that there was abundant glial tau pathology including 
astrocytic plaques, inclusions and oligodendritic coiled bodies. The NFTs were 
preferentially localized to layers II and III (supragranular layers) of the neocortex and 
were also observed in the spinal cord. Hof et al. also reported that most of the NFTs 
were located in the supragranular layers rather than the infragranular layers where 
they commonly predominate in AD. Neuropil threads have been inconsistently 
observed in PDC. The presence of -synuclein deposits more closely resemble 
frontotemporal dementia (FTD) tauopathies than AD (Winton et al., 2006).  Biee-
Scherrer et al. identified the tau isoform as a triplet of 3R and 4R isoforms similar to 
that found in AD. Transactive Response DNA Binding Protein 43 kDa (TDP-43) was 
found in dystrophic neurites as well as in neuronal and glial inclusions and Lrrk2 has 
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also been implicated in ALS/PDC (Miklossy et al., 2008).  Interestingly, Anderson et 
al. (1979) and Oyanagi et al. (1994) found a significant level of NFTs in 
asymptomatic Chamarros (Steele and McGreer, 2008), which raised the question 
whether this represents an early asymptomatic form of the disease or whether 
Chamarros are simply prone to form NFTs for some reason. 
 
6.1.6 Clinical features of ALS/PDC 
ALS is known locally on Guam as lytico (idiotic). Parkinson’s Disease is known 
as bodig (lazy). Both are uniformly fatal, usually within 5 years. Guamanian ALS is 
clinically identical to sporadic ALS while the clinical features of PDC are highly 
variable.  As noted by Steele (2005), typical symptoms and signs of the disease 
include  generalized slowing, difficulty maintaining voluntary motor activities and 
marked diminution of movements. Early symptoms include stooped posture, slurring 
of speech and slowing of gait. As the disease progresses, flexor rigidity becomes 
more prominent, particularly in the trunk and neck. The rigidity begins proximally and 
is symmetrical in the upper extremities. Fixed, rigid catatonic postures have been 
also seen in some patients.  By the late stage of the disease, generalized rigidity and 
immobility are usually pronounced. Tremor is present in many patients but never 
completely incapacitating. The tremor is localized to the hands and tends to lessen 
as the disease progresses due to increased rigidity. Patients show tremor at various 
moments (rest, action, and with changes of posture) that can be increased by 
movement or excitement and sometimes disappears with rest. In approximately one 
third of patients, the tongue is affected by tremor. Eyelid, jaw and head tremor are 
also sometimes seen. Mental changes with memory impairment and disorientation 
are common and often accompanied by personality changes and mood disorders. 
Comprehension and simple reasoning worsen with disease progression and patients 
exhibit increased confusion, and apathy. Dementia is often the dominant and 
sometimes the initial symptom. Few patients exhibit the classic pill-rolling tremor, 
micrographia, festinating gait, propulsion, retropulsion, or other features associated 
with PD (Steele, 2005). A PSP-like syndrome is a common finding in many cases of 
PDC/ALS (Steele, 2005), as is CBD (asymmetical apraxia, rigidity, limb dystonia,) 
and primary progressive aphasia.   
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Interestingly, 44% of Guamanian patients also exhibited diabetes. It has been 
hypothesized that impairment of glucose metabolism in the brain occurs much earlier 
than the clinical symptoms of neurodegenerative disease, and may lead to 
decreased O-GlcNAcylation of tau. As O-GlcNAcylation has been shown to be in 
inverse correlation to tau protein phosphorylation, this state is believed to lead to tau 
hyperphosphorylation resulting in a cascade leading to eventual neuron demise.   
 
6.1.6.1 Marianas dementia 
In 1987, Schoenberg performed surveys in three villages on Guam to assess 
prevalence rates and make a comparison with those measured 35 years before. 
Fifty-five cases of neurodegeneration in a population of 3,576 residents were 
identified (Steele, 2005). Interestingly, 19 of these cases showed only symptoms of 
dementia with a relatively late age of onset of 73. It was unsure whether this 
dementia was part of the spectrum of ALS/PDC or AD. It has been given a special 
designation: Mariana’s dementia MD). Further research was conducted from 1997-
2000 in which 194 Chamarros were tested in an attempt to differentiate between 
cortical and subcortical forms of dementia. It was determined that MD was present in 
eighty three patients; ninety were diagnosed with PDC; eleven had parkinsonism 
alone; and ten were diagnosed with ALS. MD was indistinguishable from PDC, and 
also met the inclusion criteria for the diagnosis of AD. There were too few autopsy 
studies to determine if the histopathology was that of PDC or AD or a combination of 
both (Steele, 2005) but it raised the possibility of a phenotypic switch similar to the 
one that had occurred earlier involving ALS to PDC. 
 
6.2 ALS/PDC in Japan- “Muro disease” 
6.2.1 Epidemiology 
A second focus of ALS/PDC was identified 2400 km away from Guam in 
Japan in the 1960s through an epidemiological survey conducted by Kimura and 
Kase (Yoshida et al., 1998). The incidence of ALS in this genetically and ethnically 
distinct population in the mountainous regions along the southern coast of the Kii 
Peninsula was found to be approximately 100 times higher than that of the rest of 
Japan. Two districts, Hohara (Mie prefecture) and Kozagawa (Wakayama prefecture) 
were identified as the epicentre (Kuzuhara and Kokuba, 2005). Interestingly, the first 
description of the disease ‘Ashi-nae’ (meaning paralysis of the legs) dates back to a 
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book written in the mid-17th century (Yoshida et al., 1998). A more recent survey by 
Kuzuhara and colleagues showed an ALS incidence rate of 49.4 per 100000 
between the years of 1990-1994, which didn’t differ substantially from the rate during 
1960-1979 despite reports of a declining incidence and phenotypic switch from ALS 
to PDC (Kaji et al., 2012). The crude prevalence rate for all ALS/PDC in 1998 was 
801 per 100,000 (334 PDC, 334 PDC+ALS, 133 ALS) (Kuzuhara, 2001). After a 
temporary decline in the 1980s it is evident that high prevalence rates continue 
(Kuzuhara, 2005).  
6.2.2 Etiology 
Possible causes including genetics, infection, and environmental factors have 
all been considered but none has been proven. One important hypothesis is related 
to a change in environmental factors to account for the dramatic decline in incidence 
and change in phenotype. The most likely suspect was an improvement in minerals 
in food and drinking water, as a consequence of increased westernization. Yase 
(1972) proposed that chronic nutritional deficiencies of calcium and magnesium and 
relative excess of aluminium resulted in abnormal accumulation in neurons and 
caused motor neuron degeneration. However, in subsequent studies serum calcium 
and parathyroid hormone levels have been found to be within normal limits in Hobara 
as well as on Guam. A recently published study by Kihira et al. (2015), analyzed 
scalp hair from ALS patients and controls for transition metals and found significantly 
elevated levels of zinc, vanadium, manganese, and aluminum. They hypothesize that 
long-term exposure to these metals may trigger neuronal degeneration through 
induction of oxidative stress, especially in patients with genetic vulnerabilities. 
Another study showed Kii ALS patients have elevated levels of urinary 8-
hydroxydeoxyguanosine, a marker of DNA oxidation (Morimoto et al., 2009).   
 
In an attempt to extend the cycad hypothesis to the Japanese cases, Spencer 
et al. (1987) performed two field studies in the Mie prefecture, which led to 
identification of the presence and use of cycads (C. revoluta). They reported a story 
of a young girl who played with cycad seeds every year that had been collected by 
her grandmother and died at the age of 25 from ALS. She had used them as 
marbles, and had likely ingested the seeds orally. She was healthy until the age of 18 
when she complained of backache and calf spasms. The mature seed of C. revoluta 
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was also stocked by some pharmacies that filled prescriptions written by traditional 
folk medicine practitioners (Spencer et al., 1987). 
 
Despite evidence of cycad use, the Japanese have largely pursued a genetic 
course in their research due to a greater than 70% familial occurrence. 
Environmental causes have effectively been ruled out in the minds of many 
researchers because of a case report of an 82-year-old Japanese man who had lived 
28 years on Guam and who developed PD despite his extreme exposure to the 
traditional Chamarro lifestyle (Kuzuhara, 2005). Furthermore, the report of the 
development of PDC in the child (born in Kyoto) of a man born in an endemic region 
who died from ALS helped to steer the focus towards a genetic cause (Kaji, 2012). 
Despite these cases and extensive genetic analysis, a monogenic cause of the 
disease has not yet been identified. Current thinking is that the disorder may be 
autosomal dominant with poor penetrance, indicating multifactorial inheritance.   
 
6.2.3 Neuropathology 
The neuropathological findings are identical to those of Guam ALS/PDC in 
terms of distribution but differ in density of NFTs (Mimuro et al., 2007). 
Macroscopically, the brains of ALS cases are unremarkable while those of PDC or 
combined cases show marked atrophy. The substantia nigra and locus ceruleus 
show loss of pigmented neurons in all cases (Mimuro et al. 2007). Kii PDC is 
characterized by marked cortical atrophy and neuronal loss of the anterior portion of 
the frontal and temporal lobes as well as widespread NFTs and neuropil threads, with 
the highest density in the hippocampal formation and frontal neocortex (Itoh et al., 
2003). Single-photon emission computed tomography (SPECT) shows decreased 
cerebral blood flow to the frontal and temporal lobes (Kuzuhara and Kokubo, 2005). 
The findings are similar to those of AD but differ in the paucity of senile plaques as 
well as being preferentially distributed in layers II and III of the cortex vs. layers V and 
VI in AD.  The NFTs are more widespread than those of AD, occurring throughout the 
CNS, including basal ganglia, brain stem and spinal cord (Mimuro et al., 2007).  
Hyperphosphorylated tau proteins show a triplet band pattern (60, 64, and 68 kDa) 
consisting of all 6 isoforms, confirmed using immunohistochemistry (and identical to 
AD PHF tau). Ultrastructurally they are composed of twisted PHF with a diameter of 
8-20 nm, twisted at a periodicity of 80 nm, again similar to AD PHF (Itoh et al. 2003; 
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Kuzuhara 2005). As in Guam, it has been determined that the similar topographical 
distribution of NFTs in ALS and PDC cases represent a single tauopathy (Mimuro et 
al., 2007).   
6.2.4 Clinical Symptoms 
The clinical symptoms of Kii ALS are indistinguishable from sporadic ALS in 
other parts of the world while Kii PDC is unique but identical to Guam. In cases with 
overlap, PDC usually precedes the development of ALS symptoms (Mimuro, 2007). 
The most characteristic cognitive deficit of Kii PDC was abulia/apathy (Shindo et al., 
2014).  Although sharing many similarities with Guam ALS/PDC, the disease in Kii 
differed by predominantly affecting females (Kuzuhara and Kotubo, 2005). As 
additional evidence that ALS/PDC in the Western Pacific foci is the same disease, a 
pigmentary retinopathy was identified in 33.3% of patients with Kii ALS/PDC believed 
similar though milder, to the retinopathy found in Guamanian PDC.   
 
6.3 ALS/PDC in Papua New Guinea 
A third focus of ALS/PDC was reported in New Guinea amongst the indigenous 
people of south West Papua and Irian Jaya, Indonesia. Gajdusek first reported a high 
incidence amongst the Auyu and Jakai linguistic groups and later conducted village 
surveys between 1974-81 that revealed an ALS incidence more than 10 times higher 
than either the Guamanian or Kii foci and more than 100 times higher than elsewhere 
in the world (Spencer et al., 2005). The age of onset was lower (33 years for ALS, 43 
years for PDC) compared to cases on Guam but otherwise similar. Gajdusek 
believed that the cause was most likely environmental and of natural origin due to the 
occurrence of the disease in a hunter-gatherer tribe that was not exposed to man-
made chemicals. He was amongst the authors who proposed that a mineral 
deficiency triggered a hyperparathyroid response to facilitate uptake of minerals that 
incidentally promoted the uptake of aluminium, manganese, and iron as bystanders, 
thus leading to neurodegeneration. The hypothesis has been challenged by Ahlskog 
and colleagues whose own study of Guamanian patients showed normal levels of 
parathyroid hormone, calcium, vitamin D, arsenic, cadmium, aluminium, copper, iron, 
mercury, lead and zinc in blood, hair, and nails (Spencer et al., 1987). The clinical 
and epidemiological picture mirror the situation in Guam and the Kii Peninsula but 
neuropathological evidence is lacking.  
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From 1987-1990 Spencer and colleagues carried out field studies in 6 villages, 
including the village of Bosuma, which had the highest ever reported prevalence of 
ALS (1,300/100,000) (Spencer et al., 1987). During the field studies, they made the 
discovery that cycad seed/pulp was widely used as an effective topical treatment for 
skin lesions (Spencer et al., 1987). Cycad seed materials have been experimentally 
demonstrated to speed skin repair in rodents. Also, bedridden ALS Guamanian 
patients are known to be extremely resistant to bedsores. The traditional use of 
cycads as a poultice involved: crushing the scrapings of the starchy, toxic inner 
portion of a raw seed by hand, immersing it in the milky poisonous exudate and then 
applying it directly to the lesion by means of a strap to hold it in place. It was replaced 
daily until the lesion healed. Spencer reported a case of a 29-year old man with ALS 
who recalled using the preparation for a month as taught by his mother who died 
from ALS at age 50 (Spencer et al., 1987). The surveys also revealed a decline and 
switch of ALS cases to PDC cases, from a ratio of 20:1 in 1963, to 5:1 in 1970, to 2:3 
in 1990, reminiscent of Guam and Japan. Spencer considers that the lack of change 
in the water supply makes the mineral hypothesis highly unlikely compared to the 
cycad seed use hypothesis. The decline in prevalence over the years could be 
associated with the decreased use of cycad because of the change to a village-
based lifestyle, which incurred fewer skin injuries as well as disappearance of the 
childhood skin disease of yaws. Additionally, the development of agriculture probably 
resulted in a better nutritional state. Proponents of the mineral hypothesis criticized 
cycad involvement as cycads have been used as medicine in many other populations 
and surveillance has failed to reveal any additional foci of high incidence (Garruto et 
al., 1990).    
 
 
7 Atypical Parkinson’s on Guadeloupe 
An increased frequency of atypical parkinsonism was identified on the Caribbean 
island of Guadeloupe in 1996 by Caparros-Lefebvre and colleagues (1999, 2002) in 
which the usual ratio of idiopathic to atypical Parkinson’s was found to be reversed. 
Atypical Parkinson’s (AP) has been identified as being 3.4 times more common on 
Guadeloupe than idiopathic PD with only one third of the patients reporting the classic 
symptoms of idiopathic PD. Atypical Parkinson’s syndromes account for about 20% of 
the total number of cases of parkinsonism throughout North America and Europe 
while idiopathic PD accounts for approximately 70% of all cases. Cases of AP differ 
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from idiopathic Parkinson’s disease in that they are L-DOPA-resistant (in the long-term), 
tend to evolve rapidly, and are often associated with postural disorders, supranuclear 
gaze palsy, pyramidal or cerebellar signs, alien hand syndrome, severe ideomotor 
apraxia,  early autonomic failure and early cognitive decline. Among these syndromes, 
PSP and CBD are the most common. Others include multiple-system atrophy, diffuse 
Lewy bodies disease, frontotemporal dementia, Guam PDC, and Gd-PDC/PSP. It has 
been well established that tau abnormalities play a crucial role in several 
parkinsonian disorders . One of the six regularly screened polymorphisms in the 
MAPT gene has been confirmed to be associated with sporadic Parkinson’s disease 
(Kara et al., 2012).   
 
7.1 Epidemiology 
Guadeloupe has approximately 422,000 inhabitants of whom 80% are of African 
or mixed origin, 15 % are Indian and 5% are Caucasian (Caparros-Lefebvre, 2005).  
Cases of atypical PD have been identified in all ethnic groups suggesting an 
environmental etiology. As in Guam, cases of atypical PD showed an unequal 
geographic distribution. They were concentrated in three places (Le Moule, Le 
Lamentin-Sainte-Rose, Marie-Galante) that account for a relatively small part of the 
population. One third of patients presented with possible/probable PSP and were 
diagnosed with Guadeloupean Progressive Supranuclear Palsy (Gd-PSP). The 
prevalence of PSP taking into account only the identified cases was determined to be 
14/100000, an almost three fold increase over the prevalence found elsewhere in the 
world. One third of patients were found to be unclassifiable according to standard 
diagnostic criteria and designated Guadeloupean Parkinsonism Dementia Complex 
(Gd-PDC).   
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Figure 7-1 Map of high incidence villages Guadeloupe 
Reprinted by permission Elsevier Limited (Caparros-Lefabvre, D., Steele, J. Atypical Parkinsonism on 
Guadeloupe, comparison with the parkinsonism-dementia complex of Guam, and environmental toxic 
hypotheses. Env. Toxicology and pharmacology 2005; 19:407-413.) 
 
 
Caparros-Lefebvre hypothesized a connection between consumption of soursop 
fruit/and or tea and indeed, a greater number of patients presenting with atypical 
parkinsonism reported consuming fruit and infusions of the leaves of Annona muricata 
(soursop, corossol) (OR 8.3) (Caparros-Lefebvre and Elbaz, 1999).  In an attempt to 
clarify the role of A. muricata, Lannuzel and colleagues carried out a cross sectional 
survey on 69 patients and 88 controls matched for sex and age. Consumption of fruit 
and infusions was  evaluated and expressed as fruit-years and cup-years, and then 
converted into milligrams of annonacin. The consumers were divided into groups of low 
consumers and high consumers. In the control groups, 14% reported high consumption 
of fruits and 19% high consumption of infusions, compared to 76% of Gd-PSP and 74% 
of Gd-PDC. The estimated ingested amount in the patient groups was almost 5 times 
higher than that of controls (150:33 g) (Lannuzel et al., 2007). Also, the doses 
consumed were about 20 times higher than doses used in previous experiments that 
induced widespread neuronal degeneration in rats over a period of 28 days. The seeds 
were determined to contain the highest level of neurotoxin and there was a correlation 
with seed consumption and severe, rapid progression of disease (Caparros-Lefebvre 
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and Lees, 2005). Interestingly, six patients showed improvement in their gait disorders, 
bradykinesia, and rigidity upon stopping consumption of Annonceae suggesting a 
component of reversibility to the disease. 
 
About 50% of the atypical patients were not high consumers of Annonceae 
suggesting that additional factors, environmental, genetic, or otherwise, might affect the 
vulnerability of patients to the neurotoxins. One suspected cause is organochlorine 
derivatives that were once widely used in Guadeloupe as pesticides; however, no 
epidemiological data is available. A genetic component has been proposed, but less 
than 4% of the patients have positive family histories of neurodegenerative disease. 
Additionally, a large study of the PSP-associated H1 subhaplotype showed no 
association with atypical parkinsonism in Guadeloupe (Cazumat, 2008).  
 
In support of the Annonceae neurotoxin hypothesis, clusters of AP have also been 
reported in New Caledonia (Angibaud, G et al., 2004) and in patients of Caribbean 
origin in London known to consume Annonceae (Chaudhuri, K et al. 2000). In a study in 
New Caledonia, Angibaud and collaborators, found that the frequency of atypical 
parkinsonism was elevated (accounting for approximately 50% of total cases), and that 
again, the ratio was similar between ethnic groups. They also showed that 73% of 
atypical parkinsonism patients were regular consumers of Annonaceae as opposed to 
39% of the patients with idiopathic PD. Chaudhuri identified a four fold increased risk of 
atypical parkinsonism in Carribean/East Indian immigrants to the UK prompting a 
search for genetic and/or neurotoxic etiology.   
 
7.2 Toxins in Annona muricata 
Annonaceae originated in Central America and were brought by Spanish navigators to 
the Antilles and Pacific Islands. They are widely used as alimentation and medicine 
(cardiac, digestive sedation, impotence) in tropical areas of the world but like many 
plants, contain insecticidal substances essential to their survival that are found in the 
roots, seeds, bark, fruit, stems, and leaves. Two major classes of toxins have been 
suspected to play a role in Gd-PSP/PDC: alkaloids and acetogenins.  
7.2.1 Alkaloids 
Five water-soluble alkaloid toxins have been isolated from A. muricata: four 
benzylisoquinoline alkaloids and one aporphine alkaloid. They are both substrates and 
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inhibitors of monoamine oxidase (inhibit dopamine reuptake), and some are inhibitors of 
complex I of the mitochondrial respiratory chain (Coleman et al., 1996). 1-benzyl-
1,2,3,4-tetrahydroisoquinoline alkaloids have previously been shown to induce PD in an 
animal model (Matsushige et al., 2012). Reticuline and coreximine are the most 
abundant toxins by weight and have shown dopaminergic toxicity in cell culture studies 
(Lannuzel, 2008).  In support of the role of alkaloids as potential causes of Gd-
PSP/PDC, high concentrations of endogenous benzyltetrahydroisoquinolones have 
been detected in the CSF of some parkinsonian patients (Caparros-Lefabvre and Elbaz 
1999). It is possible that the mechanism of cytotoxicity is mediated through glutamate or 
free radicals (Caparros-Lefabvre and Elbaz, 1999). Annonaine showed the most 
neurotoxicity of all the alkaloids against catecholaminergic cell lines by reduction of 
tyrosine hydroxylase activity. The concentrations of alkaloids required to cause cell 
death are relatively high and unlikely to be reached in the brains of patients, making 
their role in the causation of Gd-PSP/PDC less likely than that of the other class of 
soursop toxins, acetogenins.  
 
7.2.2 Acetogenins 
Anonaceous acetogenins are potent lipophilic inhibitors of complex I of the 
mitochondrial respiratory chain (Escobar-Khondiker et al., 2007) that are exclusively 
produced by annonaceous plants.  They constitute a unique class of polyketides and 
are the most potent mitochondrial inhibitors known to date. Thirty-four acetogenins have 
been isolated from the leaves of A. muricata. Annonacin makes up the majority 
(approximately 70%) of all acetogenins found in extracts (Champy, 2005). Annonacin 
was shown to readily cross both the BBB and the neuronal cell membrane in several 
experiments (Champy, 2004 et al., Lannuzel et al., 2003). As acetogenins are not 
actively exported from the brain parenchyma via P-glycoprotein systems in the BBB 
(Oberlies et al., 1997) and because they are highly lipophilic, it can be assumed that 
they accumulate within the brain.  
 
Annonacin, the major acetogenin in A. muricata, is 1000 times more toxic than 
reticuline and 100 times more toxic than 1-Methyl-4-Phenylpyridinium (MPP+) to 
cultured mesencephalic neurons (Lannuzel et al., 2003). A 30 nM concentration killed 
most DA neurons in midbrain cultures (Lannuzel, 2008). Its widespread effects can be 
explained by the fact that, unlike MPP+, it is not a substrate of the dopamine transporter 
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(Lannuzel, 2008). When fed to rats systemically over 28 days, annonacin penetrated 
the BBB and reduced adenosine triphosphate (ATP) levels by 44% in the cerebral 
cortex (which was not severely lesioned) and caused neuronal cell loss and gliosis in 
the brainstem and basal ganglia with a PSP-like distribution. Interestingly, there were 
no measurable behavioral changes in the same study (Champy, 2004). However, the 
degree of cell loss was less than 45% (Champy, 2004) and in parkinsonian patients it is 
generally accepted that 70% of dopaminergic neurons must be lost before motor 
symptoms become apparent (Bernheimer et al., 1973). It is estimated that the 
equivalent to the experimental dose could be attained in humans by regular 
consumption of soursop within one year.   
 
7.2.2.1 Effects of annonacin on tau  
Escobar-Khondiker et al. (2007) performed experiments in which cultured striatal 
neurons were treated with annonacin for 48 hours. They noted that beginning at a 
concentration of 50 nm there was concentration dependent neuronal cell loss and 
accumulation of tau in the cell bodies.  They also noted that incubation with annonacin 
resulted in an increase in tau protein levels that was unaffected by both inhibition of 
phosphatases and incubation with alkaline phosphatase to dephosphorylate tau.  In 
order to assess the level at which the upregulation of tau was occurring, they tested tau 
mRNA levels and found that they were not increased. The increase in tau must 
therefore regulated at a posttranscriptional level. Additionally, they found that annonacin 
does not induce the aggregation of tau, shown by a lack of thioflavin S staining, but 
does cause the somatic accumulation of tau and tau-tagged mitochondria. After 
incubation with annonacin, mitochondria started to move strictly toward the soma as 
opposed to control cells in which they moved randomly, in both anterograde and 
retrograde directions. Annoncacin was also seen to cause fragmentation of 
microtubules. By transfecting the cultures with NADH-quinone oxidoreductase 
(protecting the cells against ATP depletion by annonacin) it was shown that complex I 
inhibition is responsible for the redistribution of tau.  Also, stimulating anaerobic 
glycolysis prevents tau redistribution. To rule out the possibility that ROS are 
responsible for the redistribution of tau the cultures were pretreated with NAC or trolox 
to reduce ROS, which didn’t prevent cell death or redistribution of tau. Other ATP 
depleting toxins such as MPP+, 3-Nitropropionic Acid (3-NP), and Carbonyl Cyanide 
m-Chlorophenylhydrazone (CCCP) cause similar tau pathology but at much higher 
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concentrations (Escobar-Khondiker et al., 2007). Additionally, truncated forms of tau in 
vitro were found to cause mitochondrial fragmentation while full-length tau caused 
mitochondrial elongation (Sun and Chen, 2015). It has also been shown that inhibition 
of complex I results in the upregulation of the splicing factor SRSF2, which increases 
the expression of 4R tau in neurons (Wang and Mandelkow, 2015) possibly indicating a 
mechanism for the occurrence of a 4R-tauopathy.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.2.2.2 Inhibitors of mitochondrial complex I  
Mitochondria are involved in energy production, calcium buffering and apoptosis 
signaling pathways. It appears that localization and transport defects of mitochondria 
are important causes of disease (Schapira, 2010). Different tau isoforms influence 
mitochondrial localization within neurons in different ways and may change axonal 
mitochondrial content and/or transport (Stoothof et al., 2009). Free-radical mediated 
damage is a common cause of secondary mitochondrial mutations. The respiratory 
chain is an important source of free radicals and mtDNA is vulnerable to damage 
because it lacks a histone coat and has minimal repair facilities.  Perhaps not 
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Figure 7-2 Annonacin mechanism of toxicity 
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coincidentally, the normal human striatum is the site of the most age-related free radical 
damage in the human body (Schapira, 2010). Complex I inhibition, in addition to 
reducing ATP production, also increases free radical production, setting off an 
amplification cycle that leads to secondary mutations and further impairs mitochondrial 
function (Schapira, 2010).   
 
Although Guadelopean parkinsonism is the only tauopathy in which 
mitochondrial toxins are suspected to play a major role in causation, complex I inhibition 
is likely to be important in multiple neurodegenerative disorders. It is estimated that 
25% of Parkinson’s disease patients have a significant defect in complex 1 (Schapira, 
2010).  Defects in complex I have also been identified in platelets of some Parkinson’s 
patients (Schapira, 2010). Complex I consists of of 45 polypeptide subunits, with a total 
mass 980 kDa. It has an L-shaped structure with the hydrophobic component in the 
inner membrane and the hydrophilic arm projecting into the matrix. Based on the 
suspected association of A. muricata (a member of the family of mitochondrial complex 
I inhibitors) and Gd-PSP/PDC, several authors have tried to link other neurotoxins with 
the same mechanism of action to sporadic tauopathies. Hollerhage and colleagues 
investigated 24 different compounds that were reported in the literature to be inhibitors 
of complex I. They were grouped according to antagonism of ubiquinone, semiquinone, 
or ubiquinol as type A, B, or C respectively. They tested 22 natural substances and two 
synthetic substances. All compounds were found to be moderate to highly lipophilic and 
inhibited complex I with moderate to high intensity. After 48 hours, all substances 
induced neuronal cell death and also caused phosphorylated tau to redistribute from 
the axon to the somatodendritic compartment. They found that the redistribution was 
maximal at half the concentration with maximum toxicity and at a two- fold dilution 
lower, little or no tau redistribution occurred (Hollerhage et al., 2009). The specific 
binding site of these compounds does not appear to affect their biological effects. The 
redistribution of phosphorylated tau protein is not a specific result of complex 1 
inhibition but also by other mitochondrial toxins that lead to ATP depletion by different 
mechanisms of action. Therefore, a broad array of environmental compounds (ie. 
pesticides such as fenazaquin) leading to energy depletion might be important etiologic 
factors in sporadic tauopathies. Microorganisms (myxobacteria, Streptomyces spp.) 
produce many highly toxic complex I inhibitors and as their natural habitat is soil, there 
is a high probability that many plants are contaminated the possibility of colonization of 
the human body exists (Hollerhage, 2009).   
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7.3 Clinical Symptoms 
The clinical picture of Gd-PSP/PDC is a unique combination of levodopa-
resistant parkinsonism, tremor, hallucinations, Rapid eye movement (REM) sleep 
behavior disorder (RBD), fronto-subcortical dementia and myoclonus. Two phenotypes 
(PSP and PDC) have been defined according to the presence or absence of 
oculomotor signs. The two groups appear to constitute a single disease entity. The 
presence of several unusual symptoms (hallucinations, dysautonomia, REM sleep 
behaviour disorder and myoclonus) distinguish Gd-PS/PDC from classical PSP.  A 
study by Aspartis et al. (2008) showed a high prevalence of a very specific type of 
myoclonus among patients. It was a small amplitude, asymmetrical/unilateral, 
arrhythmic, rest- or posture-associated tremor of the distal part of the upper limb that 
did not impair motor function. The cortical origin of the myoclonus was demonstrated by 
the detection of a short-latency pre-myoclonic positivity in the sensorimotor cortex. This 
cortical myoclonus likely results from the disinhibition of the motor cortex secondary to 
basal ganglia dysfunction or intrinsic cortical pathology due to tau accumulations 
(Aspartis et al., 2008). A third possibility is that glial cells containing tau inclusions, 
interfere with regulation of the excitability of pyramidal neurons (Aspartis, 2008).   
 
A second difference between classical PSP and Gd-PSP is in regard to the type 
of oculomotor disturbance. In classical PSP, lesions in the brainstem and cerebellum 
cause reduced vertical saccade velocity, marked saccade hypometria and severely 
saccadic smooth pursuit (Aspartis et al., 2008), whereas in Gd-PSP the disturbance is 
predominantly in the cortex and affects saccade latencies and error rates. This is in 
accordance with the severity of cognitive impairments and with the distribution of 
neuropathological findings (Caparros-Lefebvre et al., 2002).  
 
In 2007, Lannuzel et al. (2007) attempted to define the characteristics of the 
clinical expression of Gd-PSP/PDC. Dementia was observed in 92% of PSP and 100% 
of PDC patients compared to 52-74% of classical PSP and involved frontal lobe 
dysfunctions including: slowness of thought, perseveration, primitive reflexes and 
apathy. Interestingly, both Guamanian and Guadeloupean patients often have 
preserved verbal comprehension up to a few days before death, unlike in AD 
(Caparros-Lefebvre et al. 2002).  Parkinsonian symptoms were symmetric at onset in 
39% of Gd-PSP and 47% of Gd-PDC and a bilateral, postural tremor was the most 
frequent initial symptom in 45% of Gd-PSP and 43% of Gd-PDC (Lannuzel et al., 
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2007). Postural instability was extremely common in both Gd-PSP (82%) and Gd-PDC 
(70%). The response to levodopa was absent or minimal in 96% of Gd-PSP and 76% of 
Gd-PDC. Rigidity is most pronounced in the axial muscles in Gd-PSP and in the limb 
muscles of Gd-PDC. Supranuclear gaze palsy was partial in 80% and complete in 12% 
of Gd-PSP patients. Urinary incontinence and orthostatic hypotension occurred about 4 
years after disease onset. Many Gd-PSP (59%) and PDC (52%) patients experienced 
hallucinations (most often visual).  
 
RBD involving insomnia, dream enactment, and violence during sleep was found 
in 78% of Gd-PSP (43% reported the disorder several years before disease onset) as 
opposed to 13%- 33% of patients with classical PSP (Lannuzel 2008 and Cochen de 
Cock et al., 2007). The high prevalence of this disorder occurring in a tauopathy when it 
has usually been associated with synucleinopathies, suggests that the location of the 
lesions rather than the protein that forms them is important for the development of RBD 
(Cochen de Cock et al., 2007).  
 
7.4 Neuroimaging of Gd-PSP/PDC 
Magnetic resonance imaging (MRI) scans were abnormal in all patients with 
atypical parkinsonism and showed widespread atrophy of both the cerebral cortex and 
the brainstem. Atrophy was most pronounced in the frontal and temporal lobes in PSP 
and in the frontal and parietal lobes in PDC and was largely symmetrical (Lannuzel et 
al., 2007).  Tectal atrophy was observed in 1/3 of PDC and PSP patients but 
mesencephalic or cerebellar atrophy was observed only in PSP.  Interestingly, 
mesencephalic atrophy was not directly associated with disease duration.  The lateral 
and third ventricles were frequently enlarged in both PDC and PSP. An MRI study by 
Lehericy and colleagues showed widespread grey matter atrophy in the cortex in Gd-
PDC,  , whereas the midbrain was relatively spared.  Structural white matter 
abnormalities have been observed in the occipital and temporal white matter, as well as 
the splenium and the cerebellum. There were widespread diffusion abnormalities in the 
cortical and subcortical areas.  PSP patients had fewer inferior frontal and medial 
temporal changes, and increased midbrain and superior cerebellar peduncle changes. 
These differences correlate with the difference in symptoms between classical PSP and 
Gd-PDC (Lehericy, 2010). The pattern of oculomotor abnormalities differs as well. The 
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presence of cortical lesions and minimal midbrain involvement provides a strong 
anatomical correlate to clinical and electrophysiological findings mentioned earlier. 
 
7.5 Pathology 
In patients with oculomotor signs, neuronal loss was found to predominate in the 
substantia nigra and the striatum (Lannuzel, 2008) and was associated with intense 
gliosis. Non-DAergic neuronal populations were also affected: frontal cortex, palladium, 
sub-thalamic nucleus and pontine nuclei. Extensive accumulation of tau was observed 
in neuronal and astrocytic processes but NFT were rare. Gel electrophoresis detected a 
major doublet of pathological tau, at 64 and 68 kDa similar to that found in PSP. Tau 
positive threads were the most abundant lesions. Astrocytic tufts were virtually absent 
as compared to classic PSP.  
 
7.6 Comparison with Guam 
In the year 2000, Steele and Caparros-Lefebvre compared Guamanian and 
Guadeloupean cases of atypical parkinsonism. They agreed that the diseases were 
very similar to one another. The pathological findings identified in 4 Guadeloupe cases 
is compatible with classical PSP with an electrophoretic profile of tau proteins in a 64-69 
kDa doublet.  In Guamanian PDC the abnormal protein was identified as a triplet of 
pathological tau components at 60, 64, and 69 kDa. However, McGreer identified 
additional forms of tau in PDC including a 64-69 kDa doublet (Caparros-Lefebvre and 
Steele, 2005).  There were a few differences found in the pathology of Gd-PSP/PDC 
and Guamanian PDC. The Guadeloupean disease showed an abundance of threads in 
white matter and a paucity of NFT in the hippocampus compared to Guamanian PDC. 
The fruits of the Annonaceae family are also commonly eaten on Guam and 
investigators have begun to evaluate their possible role in PDC in a case-control study 
(Caparros-Lefebvre and Steele, 2005). 
 
 
8 Progressive Supranuclear Palsy in Northern France 
In 2015, Caparros-Lefebvre et al. reported the first known geographical cluster of 
PSP.  They describe a cluster of PSP in Northern France at a hospital serving the 
population of the towns of Wattrelos and Leers.  For most of the 20th century, this 
area was a centre for chromate and phosphate ore processing, textile dyeing, and 
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tanning. There is a significant amount of industrial waste remaining close to 
residential areas.  The observed to expected ratio of PSP incidence was 12.3 with a 
mean age of onset of 74.3 years. The initial symptom involved gait/balance in over 
one half of patients. None of the patients were related. Western blots revealed a 
typical tau 4R doublet. The tau H1 haplotype occurred in 95% of cases. Arsenic and 
chromium are possible suspects. 
 
Progressive supranuclear palsy (PSP) or Steele-Richardson-Olzsewski 
syndrome is a member of the 4R tauopathies that affects neurons and glial cells. 
Although the H1c haplotype is the strongest genetic factor associated with it, it is not 
thought to be sufficient to cause the disease and so, most cases occur sporadically 
(Golbe, 2014). The only known risk factor is lower educational attainment (Lefebvre, 
2015).  The incidence of PSP in developed countries is 1.2/100,000 per year and the 
prevalence is 5-6/100,000. The clinical diagnostic criteria are both sensitive and 
specific but the final diagnosis must be confirmed by pathohistological analysis.  
 
PSP is characterized by parkinsonism, early postural instability and falls, vertical 
supranuclear-gaze palsy, pseudobulbar symptoms, and cognitive decline. The 
average age of onset is between 60-65 yr with fairly equal distribution between 
sexes. The median time to death is 5.9 years. Prevalence is 6/100000. The clinical 
hallmark is supranuclear ophthalmoplegia (SNO), initially affecting saccadic eye 
movements in the downward direction. The first symptoms of PSP are usually 
postural instability and falls. Cognitive changes begin in the first year and dysarthria 
and bradykinesia are the most common problems. In PSP there is accumulation of 
tau isoforms that contain four microtubule binding domains (4R) in the 64 and 69kDa 
isoforms. Microtubule function is perturbed and interferes with axonal transport. 
Impairment of mitochondrial function and oxidative damage have been suggested to 
play an important role in the pathogenesis. Free radicals induce oxidative stress, 
particularly membrane lipid peroxidation, inhibiting the dephosphorylation of tau.  
Neuropathologically, it is characterized by neuronal loss and gliosis consistently 
affecting mainly the globus pallidus, the subthalamic nucleus, and the substantia 
nigra. NFTs, pretangles, threads and tufts can be detected.  
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9 Conclusion 
Although the geographic clusters of environmental tauopathies in Guam, Japan, 
Papua New Guinea, and Guadeloupe account for a relatively small proportion of 
cases of tauopathies worldwide, understanding their pathophysiology could provide 
vital clues to the mechanism of sporadic tauopathies elsewhere in the world. Some of 
the neurotoxins described in conjunction with environmental tauopathies have a 
world wide distribution, particularly L-BMAA and complex I inhibitors, that could be 
important factors in several neurodegenerative diseases. Understanding the effects 
of such neurotoxins can lead to improved animal models as well as potential 
therapeutic targets.   
In summary, while research into the genetic components of disease is important, it is 
also vital to explore the suspected large role of environmental factors in order to 
understand and diminish the rapidly increasing burden of neurodegenerative disease.   
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